Program in Epithelial Biology, Stanford University School of Medicine, Stanford, CA, USA.
Department of Dermatology, Stanford University School of Medicine, Stanford, CA, USA.
Nat Commun. 2023 May 10;14(1):2685. doi: 10.1038/s41467-023-37993-w.
Cancer immunotherapies have revolutionized treatment but have shown limited success as single-agent therapies highlighting the need to understand the origin, assembly, and dynamics of heterogeneous tumor immune niches. Here, we use single-cell and imaging-based spatial analysis to elucidate three microenvironmental neighborhoods surrounding the heterogeneous basal cell carcinoma tumor epithelia. Within the highly proliferative neighborhood, we find that TREM2 skin cancer-associated macrophages (SCAMs) support the proliferation of a distinct tumor epithelial population through an immunosuppression-independent manner via oncostatin-M/JAK-STAT3 signaling. SCAMs represent a unique tumor-specific TREM2 population defined by VCAM1 surface expression that is not found in normal homeostatic skin or during wound healing. Furthermore, SCAMs actively proliferate and self-propagate through multiple serial tumor passages, indicating long-term potential. The tumor rapidly drives SCAM differentiation, with intratumoral injections sufficient to instruct naive bone marrow-derived monocytes to polarize within days. This work provides mechanistic insights into direct tumor-immune niche dynamics independent of immunosuppression, providing the basis for potential combination tumor therapies.
癌症免疫疗法已经彻底改变了治疗方法,但作为单一疗法的效果有限,这凸显了需要了解异质性肿瘤免疫微环境的起源、组装和动态变化。在这里,我们使用单细胞和基于成像的空间分析方法来阐明围绕异质性基底细胞癌肿瘤上皮的三个微环境邻域。在高度增殖的邻域中,我们发现 TREM2 皮肤癌相关巨噬细胞 (SCAMs) 通过肿瘤坏死因子-α/Janus 激酶-信号转导和转录激活因子 3(JAK-STAT3)信号以一种非免疫抑制依赖的方式支持一个独特的肿瘤上皮群体的增殖。SCAMs 代表了一个独特的肿瘤特异性 TREM2 群体,其特征是表面表达 VCAM1,而在正常稳态皮肤或伤口愈合过程中均不存在。此外,SCAMs 可通过多个连续的肿瘤传代积极增殖和自我繁殖,这表明其具有长期潜力。肿瘤会迅速驱动 SCAM 分化,肿瘤内注射足以在数天内指示幼稚的骨髓来源单核细胞向极化状态分化。这项工作为独立于免疫抑制的直接肿瘤免疫微环境动力学提供了机制见解,为潜在的联合肿瘤治疗奠定了基础。
Life Sci Alliance. 2021-6
Biochem Biophys Res Commun. 2022-12-25
Proc Natl Acad Sci U S A. 2025-4
Cancer Immunol Immunother. 2025-1-3
Int J Mol Sci. 2024-8-13
Nat Rev Clin Oncol. 2024-9
Nat Commun. 2022-12-6
Cell Rep. 2021-10-19
Cell Rep. 2021-10-5
Cell Stem Cell. 2021-10-7
Nat Protoc. 2021-8